|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 972.2 DKK | +0.22% |
|
-3.35% | +39.22% |
| Jul. 04 | ETF of the week: Investing in strong trends with the momentum theme |  |
| Jul. 04 | NOVO NORDISK : Deutsche Bank remains its Buy rating | ZD |
Health-care companies were more or less flat as traders awaited more updates on obesity drugs.
Medical meetings such as the coming weekend's gathering of the American Diabetes Association are increasingly dominated by news on obesity drugs from Eli Lilly, Novo Nordisk, Zealand Pharma, Altimmune, and others.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
06-17-24 1701ET
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 972.2 DKK | +0.22% | -3.35% | 624B | ||
| 942.8 DKK | +0.45% | +5.49% | 9.61B | ||
| 898.1 USD | -0.95% | -1.20% | 809B | ||
| 6.6 USD | -2.08% | +3.37% | 468M | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +39.22% | 624B | |
| +54.07% | 809B | |
| -7.05% | 351B | |
| +15.44% | 319B | |
| +5.72% | 289B | |
| +14.72% | 240B | |
| +0.74% | 219B | |
| +14.70% | 220B | |
| +7.42% | 166B | |
| -3.79% | 157B |
NOVO NORDISK A/S 
